Stonegate Investment Group LLC Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Stonegate Investment Group LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 6.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 7,297 shares of the biopharmaceutical company’s stock after acquiring an additional 460 shares during the period. Stonegate Investment Group LLC’s holdings in Gilead Sciences were worth $591,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Cetera Investment Advisers raised its stake in shares of Gilead Sciences by 9.2% in the first quarter. Cetera Investment Advisers now owns 57,967 shares of the biopharmaceutical company’s stock worth $3,446,000 after purchasing an additional 4,877 shares during the last quarter. Baird Financial Group Inc. boosted its holdings in shares of Gilead Sciences by 3.9% during the 1st quarter. Baird Financial Group Inc. now owns 448,409 shares of the biopharmaceutical company’s stock valued at $26,660,000 after acquiring an additional 16,643 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in shares of Gilead Sciences by 44.3% in the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 8,642 shares of the biopharmaceutical company’s stock worth $514,000 after acquiring an additional 2,654 shares during the period. Donaldson Capital Management LLC raised its holdings in shares of Gilead Sciences by 12.5% during the first quarter. Donaldson Capital Management LLC now owns 5,763 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 641 shares during the last quarter. Finally, Ergoteles LLC bought a new stake in Gilead Sciences in the 1st quarter worth approximately $2,304,000. 83.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 8,242 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total transaction of $702,465.66. Following the transaction, the insider now owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Gilead Sciences news, insider Johanna Mercier sold 8,242 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total transaction of $702,465.66. Following the sale, the insider now owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the transaction, the insider now directly owns 100,936 shares in the company, valued at approximately $7,386,496.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 17,242 shares of company stock worth $1,423,646. 0.21% of the stock is currently owned by company insiders.

Gilead Sciences Stock Down 1.1 %

Shares of GILD opened at $72.09 on Wednesday. The firm has a fifty day moving average price of $74.31 and a 200-day moving average price of $77.18. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The firm has a market capitalization of $89.76 billion, a P/E ratio of 16.02, a P/E/G ratio of 0.92 and a beta of 0.19. Gilead Sciences, Inc. has a 12-month low of $71.37 and a 12-month high of $87.86.

Gilead Sciences (NASDAQ:GILDGet Free Report) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). The company had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. Gilead Sciences’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the firm earned $1.67 earnings per share. Equities research analysts expect that Gilead Sciences, Inc. will post 7.07 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a yield of 4.27%. Gilead Sciences’s payout ratio is 68.44%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on GILD. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 26th. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. Mizuho reduced their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Barclays lowered their price objective on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Monday, February 12th. Finally, Cantor Fitzgerald reduced their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $85.36.

Read Our Latest Analysis on GILD

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Articles

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.